Indivior (NASDAQ:INDV – Get Free Report) is projected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Indivior to post earnings of $0.32 per share and revenue of $259.30 million for the quarter.
Indivior Price Performance
Shares of INDV stock opened at $10.91 on Thursday. Indivior has a 1 year low of $7.33 and a 1 year high of $23.22. The stock’s 50 day simple moving average is $11.56 and its two-hundred day simple moving average is $10.89. The company has a market cap of $1.50 billion, a PE ratio of -272.63 and a beta of 0.73.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the company. Rodman & Renshaw assumed coverage on Indivior in a research report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price objective on the stock. Piper Sandler restated an “overweight” rating and set a $16.00 price objective (up from $15.00) on shares of Indivior in a research report on Friday, October 25th. Finally, RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th.
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- How to Capture the Benefits of Dividend Increases
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- How to Profit From Value Investing
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.